STVNEarnings•businesswire•
Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025
Sentiment:Positive (70)
Summary
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 5, 2025 by businesswire